人 pTau231 抗体对
01AB00078
p-Tau231 is a biomarker used to detect incipient Alzheimer's disease pathology. It is a phosphorylated form of tau protein, which is primarily localized in neurons of the central nervous system and is involved in microtubule stabilization. Tau elevation is observed in the cerebrospinal fluid (CSF) of patients with neurodegenerative disease and severe head injuries, suggesting its extracellular release during neuronal damage and a role as a biomarker with specificity for brain injury. In Alzheimer's disease and related neurodegenerative diseases, including chronic traumatic encephalopathy, tau is abnormally phosphorylated and aggregated into bundles of filaments. P-Tau231 has been shown to differentiate Alzheimer's disease from healthy controls and can identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired older adults. It is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- MAPT
- 基因别名
- MAPTL; MTBT1; TAU
- 蛋白别名
- Microtubule-associated protein tau; pTau231
- UniProt
- P10636-8
- 物种
- Human
产品详情
- 靶点名称
- pTau231
- 蛋白名称
- Microtubule-associated protein tau
- 靶点基因名
- MAPT
- 基因别名
- MAPTL; MTBT1; TAU
- UniProt
- P10636-8
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
p-Tau231 is a biomarker used to detect incipient Alzheimer's disease pathology. It is a phosphorylated form of tau protein, which is primarily localized in neurons of the central nervous system and is involved in microtubule stabilization. Tau elevation is observed in the cerebrospinal fluid (CSF) of patients with neurodegenerative disease and severe head injuries, suggesting its extracellular release during neuronal damage and a role as a biomarker with specificity for brain injury. In Alzheimer's disease and related neurodegenerative diseases, including chronic traumatic encephalopathy, tau is abnormally phosphorylated and aggregated into bundles of filaments. P-Tau231 has been shown to differentiate Alzheimer's disease from healthy controls and can identify patients with AD and differentiate them from amyloid-β negative cognitively unimpaired older adults. It is a promising novel biomarker of emerging AD pathology with the potential to facilitate clinical trials.